JUPITER, Fla., Dec. 14 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").
This agreement is a continuation of the successful relationship between the two organizations which began in March 2006 when Dyadic engaged Scripps to annotate the C1 genome for the first time. The results of this initial project, in combination with advances made by Dyadic, have provided necessary information for Dyadic to discover and develop more efficient enzyme products and solutions. It also established C1 as a versatile technology platform (the "C1 Platform Technology") which has subsequently been licensed by Dyadic on a non-exclusive basis to Abengoa Bioenergy New Technologies, Inc. and Codexis, Inc. to produce enzymes and proteins on a commercial scale at higher yields and at lower costs.
Since the initial annotation project, the genomic and computational tools available to Scripps and Dyadic have improved. During this time, Dyadic has also re-sequenced its C1 genome which has provided greater knowledge of this novel organism. Lastly, the worldwide scientific community has been very active over the last few years in sequencing the genomes of a multitude of living organisms. Together, these advances now provide the impetus for Dyadic to further improve the productivity and efficiency of its patented and proprietary C1 Platform Technology by re-annotating the C1 genome and leveraging the most current scientific data. Dyadic intends to use this research to continue developing and manufacturing enzyme products for the bioenergy, food and feed, pulp and paper, and textile markets while also leveraging its technologies for use in the biopharmaceutical, cosmetic and nutraceutical industrie
|SOURCE Dyadic International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved